Hyperglycemia in Pregnant Diabetic Patients
Conditions
Brief summary
Our objective is to assess whether pre-treatment with a fixed dose of insulin, based on weight, given to pregnant patients with gestational or preexisting diabetes receiving betamethasone can provide adequate glycemic control. Our hypothesis is that pre-treatment with a weight-based calculated insulin dose will help maintain euglycemia for pregnant patients with gestational and preexisting diabetes after steroid administration, and possibly impact length of hospital admission.
Interventions
DRUGinsulin pre-treatment
insulin pre-treatment of pregnant diabetic patients who receive betamethasone
Sponsors
University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Pregnant women with gestational or pre-existing diabetes admitted to the University of Minnesota 2. Must be 18 years or older 3. Must speak English, Spanish, or Somali 4. Patients must receive steroids for fetal lung maturity as part of their hospital course
Exclusion criteria
1. Pregnant women with Type 1 Diabetes, or Type 2 diabetes with evidence of end-organ disease 2. Pregnant women who need to be emergently delivered due to maternal or fetal complications of pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of hospital days until euglycemia in pregnant diabetic patients receiving steroids who are pre-treated with insulin. | number of hospital days | Pregnant diabetic patients admitted to the hospital who receive steroids for fetal lung maturity will have their blood glucose levels checked before and after receiving steroids. Blood glucose levels will be checked fasting and postprandial until the levels are consistently less than 160. This will vary for patients, but will be on average 2 to 14 days. |
Countries
United States
Outcome results
None listed